Market Assessment
Eli Lilly (LLY) is a large-cap ($102.6B) biopharma known for innovative and diverse therapeutics for diseases affecting the endocrine system, immune system, and the brain. Its oncology products are broad with therapeutics for cancers affecting non-small cell lung, colon, head and neck, pancreas, breast, ovary, bladder, and gut.
Developing liver therapeutics does not appear to be of significant clinical interest to Eli Lilly. As a matter of fact, Eli Lilly does not have a clinical program for liver diseases. For this reason, the initiation of a Phase 2 study of baricitinib